Description of combined ARHSP/JALS phenotype in some patients with SPG11 mutations. Issue 7 (8th May 2020)

• Record Type: Journal Article
• Authors: Khani, Marzieh; Shamshiri, Hosein; Fatehi, Farzad; Rohani, Mohammad; Haghi Ashtiani, Bahram; Akhoundi, Fahimeh Haji; Alavi, Afagh; Moazzeni, Hamidreza; Taheri, Hanieh; Ghani, Mina Tolou; Javanparast, Leila; Hashemi, Seyyed Saleh; Haji‐Seyed‐Javadi, Ramona; Heidari, Matineh; Nafissi, Shahriar; Elahi, Elahe
• Is Part Of: Molecular genetics & genomic medicine. Volume 8:Issue 7(2020)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2020-05-08
• Subjects: ALS -- ARHSP -- autosomal recessive hereditary spastic paraplegia -- juvenile amyotrophic lateral sclerosis -- SPG11; Medical genetics -- Periodicals; Genomics -- Periodicals; 616.042
• DOI: 10.1002/mgg3.1240
• Languages: English
• ISSNs: 2324-9269

Abstract

Abstract: Background: SPG11 mutations can cause autosomal recessive hereditary spastic paraplegia (ARHSP) and juvenile amyotrophic lateral sclerosis (JALS). Because these diseases share some clinical presentations and both can be caused by SPG11 mutations, it was considered that definitive diagnosis may not be straight forward. Methods: The DNAs of referred ARHSP and JALS patients were exome sequenced. Clinical data of patients with SPG11 mutations were gathered by interviews and neurological examinations including electrodiagnosis (EDX) and magnetic resonance imaging (MRI). Results: Eight probands with SPG11 mutations were identified. Two mutations are novel. Among seven Iranian probands, six carried the p.Glu1026Argfs*4‐causing mutation. All eight patients had features known to be present in both ARHSP and JALS. Additionally and surprisingly, presence of both thin corpus callosum (TCC) on MRI and motor neuronopathy were also observed in seven patients. These presentations are, respectively, key suggestive features of ARHSP and JALS. Conclusion: We suggest that rather than ARHSP or JALS, combined ARHSP/JALS is the appropriate description of seven patients studied. Criteria for ARHSP, JALS, and combined ARHSP/JALS designations among patients with SPG11 mutations are suggested. The importance of performing both EDX and MRI is emphasized. Initial screening for p.Glu1026Argfs*4 may facilitate SPG11 screenings in Iranian patients. Abstract : Nineteen patients of eight families with SPG11 mutations are described. Two previously unreported SPG11 mutations are reported. Definitive diagnosis of ARHSP or JALS is sometimes very difficult. Rather than ARHSP or JALS, combined ARHSP/JALS is the appropriate description for some patients with SPG11 mutation. Criteria for ARHSP, JALS, and combined ARHSP/JALS designations among patients with SPG11 mutations are suggested.